John Crowley, PhD
The multiple sclerosis market is evolving. Oral DMTs have partially fulfilled pent-up demand for alternatives to the time-tested injectable products, and potent MAbs are entering the market as neurologists increasingly question the escalation paradigm in MS treatment. The first generic DMT is available in the United States—with others looming—as novel products and follow-ons are set to compete within an already complex treatment algorithm. Meanwhile, developers have re-sharpened their focus on neuroprotective treatments and therapies for the perennially underserved progressive MS population.
I cover the neurology space as a member of the CNS and Ophthalmology team at DRG. I focus primarily on multiple sclerosis and epilepsy, and my work entails forecasting, primary market research, and market access, among other topics. I have been with DRG since 2011.
I hold a Ph.D. from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute. Previously, I was a postdoctoral fellow at Harvard Medical School studying mechanisms that regulate the strength and dynamics of synapses.